Status:
RECRUITING
Improving Obsessive-compulsive Disorder Treatments: from Lesions to Neuromodulation Targets
Lead Sponsor:
Fundacao Champalimaud
Conditions:
Obsessive-Compulsive Disorder
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
While in most cases of obsessive-compulsive disorder (OCD) a cause cannot be identified, this syndrome may develop as a consequence of focal brain lesions. Neuropsychiatric disorders secondary to brai...
Detailed Description
In this study, we hypothesize that the cortical region identified from connectivity networks associated with lesional OCD may be a more effective TMS stimulation site than the one currently used in OC...
Eligibility Criteria
Inclusion
- Age between 18 and 75 years;
- Established diagnosis of Obsessive-Compulsive Disorder according to Diagnostic and statistical manual of mental disorders 5 (DSM5) criteria;
- Capacity to give consent;
- Fluent in Portuguese and/or English;
- If potential for pregnancy, agrees to use an effective method of contraception throughout the study period.
Exclusion
- Obsessive-compulsive symptoms severity assessed at baseline visit with the instrument Yale-Brown Obsessive Compulsive Scale - II (YBOCS-II) ≤ 24;
- Presence of uncontrolled active medical illness;
- Known structural lesion of the central nervous system;
- Electric or metallic implants in the body not compatible with electromagnetic radiation;
- Electric or metallic brain implants;
- Cardiac implants;
- Epilepsy;
- Pregnant, breastfeeding, or planning pregnancy women;
- Alcohol or substance abuse and/or dependence;
- Major Neurocognitive Disorder;
- Developmental disorders with low intelligence quotient or any other form of cognitive deficit;
- Active neurological disease;
- Individuals presenting with any psychotic or mood disorder requiring hospitalization at the time of eligibility criteria assessment;
- Contraindication for performing MRI;
- Individuals who have already been treated for OCD with TMS;
- Any other reason that renders the individual unable to provide informed consent.
Key Trial Info
Start Date :
November 7 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06490965
Start Date
November 7 2024
End Date
December 31 2026
Last Update
November 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Champalimaud Foundation
Lisbon, Portugal, 1400-038